When retired Yale professor of economics Martin Shubik was diagnosed with inclusion body myositis (IBM) in 2003, very little was known about the disease. At the time, few professional resources had answers to simple questions like “What can I expect from this disease?”
Continue Reading
Corbus Pharmaceuticals is now recruiting dermatomysitis patients for an exciting phase 3 clinical trial for lenabasum. The trial, known as DETERMINE, is designed to evaluate the efficacy and safety of lenabasum for the treatment of dermatomyositis.
Continue Reading
Excitement is building for Corbus Pharmaceutical’s Phase 3 clinical trial testing the safety and effectiveness of their new drug lenabasum in dermatomyositis patients.
Continue Reading
There is good news for IBM patients who want to participate in the arimoclomol clinical trial.
Continue Reading
Corbus Pharmaceuticals announced today that the European Union has approved orphan designation for lenabasum for the treatment of dermatomyositis.
Continue Reading